NCT02060396View on ClinicalTrials.gov

Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

Acetylsalicylic acid

One tablet of Adiro 100 mg will be administered daily orally for 7 days.

Trial Locations (1)

50009

Hospital clinico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Aragon Institute of Health Sciences

OTHER

NCT02060396 - Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action | Biotech Hunter | Biotech Hunter